确定滤泡淋巴瘤的基因亚型。

IF 12.9 1区 医学 Q1 HEMATOLOGY
Victoria Shelton, Rajesh Detroja, Ting Liu, Keren Isaev, Anjali Silva, Verena Passerini, Mehran Bakhtiari, Lourdes Calvente, Michael Hong, Michael Y He, Saloni Modi, Samantha A Hershenfeld, Maja Ludvigsen, Charlotte Madsen, Stephen Hamilton-Dutoit, Francesco Annibale d'Amore, Marianne Brodtkorb, Nathalie A Johnson, Tara Baetz, David LeBrun, Josh W D Tobin, Maher K Gandhi, Andrew J Mungall, Wei Xu, Susana Ben-Neriah, Christian Steidl, Jan Delabie, Rosemarie Tremblay-LeMay, Opeyemi Jegede, Oliver Weigert, Brad Kahl, Andrew M Evens, Robert Kridel
{"title":"确定滤泡淋巴瘤的基因亚型。","authors":"Victoria Shelton, Rajesh Detroja, Ting Liu, Keren Isaev, Anjali Silva, Verena Passerini, Mehran Bakhtiari, Lourdes Calvente, Michael Hong, Michael Y He, Saloni Modi, Samantha A Hershenfeld, Maja Ludvigsen, Charlotte Madsen, Stephen Hamilton-Dutoit, Francesco Annibale d'Amore, Marianne Brodtkorb, Nathalie A Johnson, Tara Baetz, David LeBrun, Josh W D Tobin, Maher K Gandhi, Andrew J Mungall, Wei Xu, Susana Ben-Neriah, Christian Steidl, Jan Delabie, Rosemarie Tremblay-LeMay, Opeyemi Jegede, Oliver Weigert, Brad Kahl, Andrew M Evens, Robert Kridel","doi":"10.1038/s41408-024-01111-w","DOIUrl":null,"url":null,"abstract":"<p><p>Follicular lymphoma (FL) exhibits considerable variability in biological features and clinical trajectories across patients. To dissect the diversity of FL, we utilized a Bernoulli mixture model to identify genetic subtypes in 713 pre-treatment tumor tissue samples. Our analysis revealed the existence of five subtypes with unique genetic profiles that correlated with clinicopathological characteristics. The clusters were enriched in specific mutations as follows: CS (CREBBP and STAT6), TT (TNFAIP3 and TP53), GM (GNA13 and MEF2B), Q (quiescent, for low mutation burden), and AR (mutations of mTOR pathway-related genes). The subtype Q was enriched for patients with stage I disease and associated with a lower proliferative history than the other subtypes. The AR subtype was unique in its enrichment for IgM-expressing FL cases and was associated with advanced-stage and more than 4 nodal sites. The existence of subtypes was validated in an independent cohort of 418 samples from the GALLIUM trial. Notably, patients assigned to the TT subtype consistently experienced inferior progression-free survival when treated with immunochemotherapy. Our findings offer insight into core pathways distinctly linked with each FL cluster and are expected to be informative in the era of targeted therapies.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"14 1","pages":"128"},"PeriodicalIF":12.9000,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11306633/pdf/","citationCount":"0","resultStr":"{\"title\":\"Identification of genetic subtypes in follicular lymphoma.\",\"authors\":\"Victoria Shelton, Rajesh Detroja, Ting Liu, Keren Isaev, Anjali Silva, Verena Passerini, Mehran Bakhtiari, Lourdes Calvente, Michael Hong, Michael Y He, Saloni Modi, Samantha A Hershenfeld, Maja Ludvigsen, Charlotte Madsen, Stephen Hamilton-Dutoit, Francesco Annibale d'Amore, Marianne Brodtkorb, Nathalie A Johnson, Tara Baetz, David LeBrun, Josh W D Tobin, Maher K Gandhi, Andrew J Mungall, Wei Xu, Susana Ben-Neriah, Christian Steidl, Jan Delabie, Rosemarie Tremblay-LeMay, Opeyemi Jegede, Oliver Weigert, Brad Kahl, Andrew M Evens, Robert Kridel\",\"doi\":\"10.1038/s41408-024-01111-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Follicular lymphoma (FL) exhibits considerable variability in biological features and clinical trajectories across patients. To dissect the diversity of FL, we utilized a Bernoulli mixture model to identify genetic subtypes in 713 pre-treatment tumor tissue samples. Our analysis revealed the existence of five subtypes with unique genetic profiles that correlated with clinicopathological characteristics. The clusters were enriched in specific mutations as follows: CS (CREBBP and STAT6), TT (TNFAIP3 and TP53), GM (GNA13 and MEF2B), Q (quiescent, for low mutation burden), and AR (mutations of mTOR pathway-related genes). The subtype Q was enriched for patients with stage I disease and associated with a lower proliferative history than the other subtypes. The AR subtype was unique in its enrichment for IgM-expressing FL cases and was associated with advanced-stage and more than 4 nodal sites. The existence of subtypes was validated in an independent cohort of 418 samples from the GALLIUM trial. Notably, patients assigned to the TT subtype consistently experienced inferior progression-free survival when treated with immunochemotherapy. Our findings offer insight into core pathways distinctly linked with each FL cluster and are expected to be informative in the era of targeted therapies.</p>\",\"PeriodicalId\":8989,\"journal\":{\"name\":\"Blood Cancer Journal\",\"volume\":\"14 1\",\"pages\":\"128\"},\"PeriodicalIF\":12.9000,\"publicationDate\":\"2024-08-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11306633/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Cancer Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41408-024-01111-w\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Cancer Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41408-024-01111-w","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

滤泡性淋巴瘤(FL)的生物学特征和临床轨迹在不同患者之间表现出相当大的差异。为了剖析滤泡性淋巴瘤的多样性,我们利用伯努利混合物模型识别了 713 份治疗前肿瘤组织样本中的遗传亚型。我们的分析表明存在五种亚型,它们具有与临床病理特征相关的独特遗传特征。这些群组富含以下特定突变:CS(CREBBP 和 STAT6)、TT(TNFAIP3 和 TP53)、GM(GNA13 和 MEF2B)、Q(静止型,突变负荷低)和 AR(mTOR 通路相关基因突变)。与其他亚型相比,Q 亚型多见于疾病处于 I 期的患者,且与较低的增殖史相关。AR亚型的独特之处在于其富集于IgM表达的FL病例,并与晚期和4个以上结节部位相关。来自 GALLIUM 试验的 418 份样本组成的独立队列验证了亚型的存在。值得注意的是,被归入TT亚型的患者在接受免疫化疗时,其无进展生存率一直较低。我们的研究结果让人们深入了解了与每个 FL 簇明显相关的核心通路,并有望在靶向疗法时代提供更多信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Identification of genetic subtypes in follicular lymphoma.

Identification of genetic subtypes in follicular lymphoma.

Follicular lymphoma (FL) exhibits considerable variability in biological features and clinical trajectories across patients. To dissect the diversity of FL, we utilized a Bernoulli mixture model to identify genetic subtypes in 713 pre-treatment tumor tissue samples. Our analysis revealed the existence of five subtypes with unique genetic profiles that correlated with clinicopathological characteristics. The clusters were enriched in specific mutations as follows: CS (CREBBP and STAT6), TT (TNFAIP3 and TP53), GM (GNA13 and MEF2B), Q (quiescent, for low mutation burden), and AR (mutations of mTOR pathway-related genes). The subtype Q was enriched for patients with stage I disease and associated with a lower proliferative history than the other subtypes. The AR subtype was unique in its enrichment for IgM-expressing FL cases and was associated with advanced-stage and more than 4 nodal sites. The existence of subtypes was validated in an independent cohort of 418 samples from the GALLIUM trial. Notably, patients assigned to the TT subtype consistently experienced inferior progression-free survival when treated with immunochemotherapy. Our findings offer insight into core pathways distinctly linked with each FL cluster and are expected to be informative in the era of targeted therapies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
16.70
自引率
2.30%
发文量
153
审稿时长
>12 weeks
期刊介绍: Blood Cancer Journal is dedicated to publishing high-quality articles related to hematologic malignancies and related disorders. The journal welcomes submissions of original research, reviews, guidelines, and letters that are deemed to have a significant impact in the field. While the journal covers a wide range of topics, it particularly focuses on areas such as: Preclinical studies of new compounds, especially those that provide mechanistic insights Clinical trials and observations Reviews related to new drugs and current management of hematologic malignancies Novel observations related to new mutations, molecular pathways, and tumor genomics Blood Cancer Journal offers a forum for expedited publication of novel observations regarding new mutations or altered pathways.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信